Tech Company Financing Transactions
Apogee Therapeutics Funding Round
On 12/7/2022, Apogee Therapeutics raised $149 million in Series B investment from Deep Track Capital, RTW Investments and private investors.
Transaction Overview
Company Name
Announced On
12/7/2022
Transaction Type
Venture Equity
Amount
$149,000,000
Round
Series B
Investors
Deep Track Capital (Lead Investor)
RTW Investments (Lead Investor)
Proceeds Purpose
Apogee will funnel some money toward filling key leadership, science and clinical team roles. It will also use its funds to help advance its lead pipeline program from Paragon to the clinic next year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA Undisclosed
USA
San Francisco, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Apogee Therapeutics, Inc. is a biotechnology company advancing novel therapies to address patients' needs. Based in San Francisco and backed by leading life sciences funds, the company expects its lead pipeline program to enter clinical trials in 2023.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Henderson
Browse more venture capital transactions:
Prev: 12/7/2022: BreezeML venture capital transaction
Next: 12/7/2022: Maergo venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs